Examkin

Soru

Zorluk: ZorNeonatal Disorders

A 4-day-old male neonate, born at 39 weeks gestation, is currently in the neonatal intensive care unit. He was admitted 48 hours ago for temperature instability, tachypnea, and poor feeding. A full sepsis workup was performed at admission, and empiric intravenous ampicillin and gentamicin were initiated. The infant is now clinically stable, feeding well, and afebrile. Today, the admission blood culture is finalized and demonstrates heavy growth of Streptococcus agalactiae (Group B Streptococcus) that is sensitive to penicillin, ampicillin, cefotaxime, and vancomycin. The cerebrospinal fluid culture remains sterile. During morning rounds, the nurse notes a new rash on the infant's chest and back consisting of scattered 2-mm to 3-mm erythematous macules, some with central pale-yellow pustules. The infant appears completely unbothered by the rash. A Wright-Giemsa stain of the pustular contents shows numerous eosinophils and no bacteria. Which of the following is the most appropriate next step in the management of this patient?

  1. Discontinue gentamicin and transition to intravenous penicillin G monotherapyCevap
  2. B
    Continue intravenous ampicillin and gentamicin for a complete 10-day course
  3. C
    Change the antibiotic regimen to intravenous vancomycin and cefotaxime
  4. D
    Add intravenous acyclovir and obtain viral surface swabs
  5. E
    Discontinue all antibiotics and observe for 24 hours prior to discharge

Cevap

Discontinue gentamicin and transition to intravenous penicillin G monotherapy
The correct next step is to discontinue gentamicin and transition to intravenous penicillin G monotherapy. The neonate has two distinct clinical issues: confirmed Group B Streptococcus (GBS) bacteremia and a new-onset rash. For the GBS bacteremia, the patient is clinically stable and sensitivities are known. Antibiotic stewardship mandates de-escalation from empiric broad-spectrum coverage (ampicillin and gentamicin) to targeted narrow-spectrum therapy (penicillin G) to minimize toxicity and resistance. The new rash, characterized by erythematous macules with central pale-yellow pustules containing eosinophils, is a classic presentation of Erythema Toxicum Neonatorum (ETN). ETN is a benign, self-limiting condition that typically appears in the first week of life and requires no pharmacologic intervention.

Adım Adım Çözüm

1
Evaluate the patient's current clinical status and blood culture results.
The patient has confirmed Group B Streptococcus (GBS) bacteremia with known sensitivities and is clinically improving.
Determines the primary diagnosis and need for targeted antibiotic therapy.
2
Apply principles of antibiotic stewardship to the current regimen.
The empiric regimen of ampicillin and gentamicin should be de-escalated to penicillin G monotherapy.
Reduces the risk of antibiotic resistance and potential toxicity from broad-spectrum agents.
3
Analyze the new-onset pustular rash using clinical and microscopic findings.
The rash is identified as Erythema Toxicum Neonatorum (ETN) due to its clinical appearance and eosinophil predominance on the smear.
Distinguishes a benign, self-limiting condition from a true secondary infection.
4
Synthesize the findings to select the next best step.
Transition to penicillin G for the GBS bacteremia and provide reassurance without additional treatment for the ETN.
Ensures appropriate targeted treatment while avoiding unnecessary interventions.

Anahtar Kavram

Neonatal Early-Onset Sepsis Management and Benign Neonatal Rashes
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Neonatal Disorders

Bu konudan daha fazla soru